A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This single arm study will determine the effects of complete anemia correction in anemic
patients with end-stage renal disease currently receiving suboptimal doses of NeoRecormon.
Patients on dialysis receiving NeoRecormon, and with a hemoglobin level <105g/L, will be
treated with subcutaneous NeoRecormon at a dose determined by the investigator in order to
reach (within 3 months) and maintain a hemoglobin level in the range of 120-135g/L. Heart
function and quality of life will be measured before and after anemia correction. The
anticipated time on study treatment is 3-12 months, and the target sample size is 100
individuals.